Before you vote › Federal bills

H.R. 1532: Scientific EXPERT Act of 2025

119th Congress · introduced 2025-02-24 · Health · Latest: Referred to the House Committee on Energy and Commerce.

federal

Save to my notebook What does this mean? Print

Official title

Scientific EXPERT Act of 2025

Plain summary

Scientific External Process for Educated Review of Therapeutics Act of 2025 or the Scientific EXPERT Act of 2025 This bill requires the Food and Drug Administration (FDA) to facilitate and participate in externally led, science-focused drug development meetings to discuss the development of treatments for rare diseases and conditions. The FDA must enter into an arrangement with the Reagan-Udall Foundation for the FDA under which the foundation agrees to convene such meetings. Meetings must be held at least four times a year, and each meeting must focus on a different rare disease or condition. The foundation must establish a permanent steering committee to review and recommend topics for each meeting. In evaluating potential topics, the committee must consider unmet therapeutic needs, patient population sizes for different diseases and conditions, and whether a disease or condition would benefit from clarity and alignment on drug development questions, among other factors. In planning each meeting, the foundation must develop a list of medical experts, drug sponsors, scientific organizations, patient organizations, and other entities to be invited to participate. Representatives of the FDA’s review divisions must attend each meeting. After each meeting, the foundation must make available a summary of the meeting noting areas of consensus, areas where additional clarification or information is needed, and next steps agreed upon with the FDA. The bill also requires the FDA to indicate whether it incorporated any input from these meetings when approving a new drug or biologic.

Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.

What a vote does

PSI Sci description of the legislative step (not an opinion).

The strongest published arguments

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

Officials and money

Sponsor: Rep. Matsui, Doris O. [D-CA-7] · 9 cosponsors

Money: No cost estimate published yet. No linked contracts or vendors yet.

Sources

• Congressional Research Service summary (Introduced in House)
• Congress.gov
• Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-119hr1532.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/119/hr>

Record fed-us-cong119-hr1532 · catalog fed-us-congress-bills-cong119 · updated 2026-11-03 by psicol fed-bills